Home/Bulletin of Pharmaceutical Sciences. Assiut University/Article Record
Peer-Reviewed Article June 29, 2012

DESIGN AND SYNTHESIS OF NEW EGFR- TYROSINE KINASE INHIBITORS CONTAINING PYRAZOLO[3,4-d]PYRIMIDINE CORES AS ANTICANCER AGENTS

Are you an author of this work?Link to your sovereign AfriScholar profile
Published in: Bulletin of Pharmaceutical Sciences. Assiut University
Publisher: Assiut University, Faculty of Pharmacy • Egypt • 1110-0052 • 3009-7703
DOI: https://doi.org/10.21608/bfsa.2012.64596

Abstract

New designed EGFR inhibitors (7-11) were prepared from the pyrazolo[3,4-d]pyrimidine intermediates 4a-d including different moieties. All newly synthesized compounds were confirmed by elemental analyses and spectral data. The molecular simulation docking to protein tyrosine kinase (EGFR), using erlotinib (Tarceva TM) as a lead compound was also studied. Some of the prepared compounds were screened for in-vitro cytotoxic activity. The docking results were in coincidence with the biological results that indicated compound 7a showed an inhibitory activity against human breast carcinoma cell line (MCF-7) [IC50 (14.86μM)].

Download Full Text PDFView at PublisherCrossref RecordCrossref XML

Verified Citation Velocity

Recorded scholarly citations in African and international peer-reviewed literature

27
Total Citations

Citations are continuously tracked and harvested across continental OJS endpoints and OpenAlex feeds.